MK 0493
Alternative Names: MK-0493Latest Information Update: 22 Aug 2006
At a glance
- Originator Merck & Co
- Class Anorectics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 01 Aug 2006 Discontinued - Phase-II for Obesity in USA (unspecified route)
- 11 Jan 2005 Phase-II clinical trials in Obesity in USA (unspecified route)